Griseofulvin for Onychomycosis: Dosing, Duration, and Monitoring
Griseofulvin should generally NOT be your first-line choice for onychomycosis due to its lower efficacy and higher relapse rates compared to terbinafine and itraconazole, but when used, dose it at 500-1000 mg daily with fatty food for 6-9 months for fingernails and 12-18 months for toenails. 1
When to Consider Griseofulvin
The British Association of Dermatologists gives griseofulvin only a Strength C recommendation, explicitly noting its inferior performance 1. Consider it only as a second-line option when:
- Terbinafine and itraconazole are contraindicated or not tolerated
- Patient has liver impairment that precludes other agents
- Cost is a major barrier (though treatment duration makes this questionable)
Important caveat: Research confirms griseofulvin achieves only ~30% cure rates even with long-term use, compared to >80% with terbinafine 2. One study showed that after 48 weeks of griseofulvin treatment, only 39% maintained cure at follow-up versus 60% with terbinafine (which required only 24 weeks of treatment) 3.
Dosing Regimen
Adults
- Dose: 500-1000 mg daily 1
- Fingernail infections: 6-9 months of continuous therapy
- Toenail infections: 12-18 months of continuous therapy
- Critical administration detail: Must be taken with fatty food to increase absorption 1, 4
Children (Age 1 month and above)
- Dose: 10 mg/kg per day (maximum 500 mg) 1
- Administration: With fatty food
- Position in therapy: Second-line after itraconazole and terbinafine 1
The pediatric data shows higher cure rates in children than adults, likely due to faster nail growth and thinner nail plates 1.
Monitoring Requirements
Baseline monitoring:
- Liver function tests (contraindicated in active liver disease) 1
During therapy:
- No specific routine monitoring is mandated in the guidelines for patients without pre-existing liver disease
- Monitor for peripheral neuropathy, especially if treatment exceeds 6 months 4
- Discontinue if granulocytopenia occurs 4
Key Clinical Pitfalls
Duration trap: The extraordinarily long treatment duration (up to 18 months for toenails) leads to poor compliance and treatment failure. Historical data from the 1960s showed that even with 1 year of continuous treatment, complete cure of toenail infections was rare 5, 6.
Absorption issues: Griseofulvin has highly variable absorption (27-72%) 4. Failure to take it with fatty food dramatically reduces efficacy. In pediatric studies, taking griseofulvin with milk increased peak serum concentrations 4-fold 4.
Relapse rates: Even when initial response occurs, relapse rates are significantly higher than with newer agents 1, 3.
Peripheral neuropathy risk: This adverse effect correlates with treatment duration and may not fully resolve after discontinuation 4. Given the 12-18 month treatment course required for toenails, this is a real concern.
Contraindications and Cautions
- Absolute contraindication: Active or chronic liver disease 1
- Caution: Pre-existing systemic lupus erythematosus (risk of nephrosis) 4
- Drug interactions: Induces hepatic enzymes, affecting multiple medications 4
Common Adverse Effects
Most frequently reported 4:
- Hypersensitivity reactions (rashes, urticaria)
- Gastrointestinal upset (nausea, vomiting, diarrhea)
- Headache
- Peripheral neuropathy (especially >6 months treatment)
The Bottom Line on Efficacy
The evidence is clear that griseofulvin is inferior to modern alternatives. A 1995 randomized controlled trial demonstrated that 24 weeks of terbinafine achieved 81% mycological cure versus 62% with 48 weeks of high-dose griseofulvin (1000 mg daily) 3. You're asking patients to take medication twice as long for worse outcomes.
In pediatric populations, where griseofulvin was historically preferred, current guidelines now recommend itraconazole or terbinafine as first-line, relegating griseofulvin to second-line status 1.